Breakthrough Melanoma Treatment, Keytruda, Developed Using Antibody Humanization Expertise at UK’s MRC Technology

MRC Technology is pleased to highlight that today Merck, known as MSD outside the United States and Canada, announced FDA approval and subsequent United States (US) commercial availability of Keytruda (pembrolizumab), an immunotherapy treatment for advanced melanoma. UK based scientists at MRCT, with extensive expertise in antibody engineering techniques, first advanced the antibody-based treatment and carried out humanization, an essential step in the success of the therapeutic.

MRC Technology Announces Humanization of Anti-Tau Monoclonal Antibody for Alzheimer’s Disease Therapy

Antibody inhibits Tau aggregation involved in the pathology of Alzheimer’s and other neurodegenerative diseases

MRC Technology and AstraZeneca renew collaboration to identify novel targets for discovery research

The collaboration focuses on the identification and selection of novel drug targets with the potential to become potent and selective therapeutics for the treatment of serious disease in the areas of oncology, inflammation and diabetes.

Dementia Consortium wins One Nucleus BioNewsRound Award at ON Helix 2014

The award was given for the announcement of the formation of a £3m Dementia Consortium in collaboration with Alzheimer’s Research UK (ARUK), and pharma partners Eisai and Lilly.

MRC Technology sells its melanocortin receptors programme to Pfizer Inc

The melanocortin receptors (MCRs) programme includes a set of small molecules and targets for these small molecules came from Mauro Perretti, Professor of Immunopharmacology at Queen Mary University of London (QMUL).

MRC Technology and Daiichi Sankyo collaborate to identify novel targets for drug discovery

MRC Technology has established a drug discovery collaboration with Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan. The agreement will focus on the identification and selection of novel drug targets with the potential to become potent and selective therapeutics including oncology, cardiovascular and metabolic diseases.

16 applications received for first Dementia Consortium deadline

The Dementia Consortium has got off to a great start, with 16 applications received for the first review deadline on 23 March. Of these, two have been asked to reapply with additional information and four have progressed to the second round of review, with decisions expected in July.

MRC Technology and Chinese Academy of Science extend collaboration to identify new targets for drug discovery

MRC Technology has extended its existing drug discovery collaboration with the Shanghai Institute of Biotechnology and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). MRC Technology will give SIBCB access to its unique compound library which will be used to screen novel targets derived from SIBCB research.

UCB and UK’s MRC Technology sign exclusive license agreement for a fibrosis programme

UCB and MRC Technology announced today that they have entered an exclusive license agreement, with UCB obtaining rights in a novel fibrosis therapy program. The program stems from a collaboration between MRC Technology’s Centre for Therapeutics Discovery and leading academics at the University of Sheffield on development of a novel antibody-based therapy which targets a key step in the progression of fibrosis.